Liraglutide
Neutral, BioHarmony verdict
BioHarmony score 5.2 out of 10
Liraglutide is a once-daily prescription GLP-1 receptor agonist. In the 3,731-person SCALE trial, 3.0 mg with lifestyle counseling produced 8.4 kg mean weight loss versus 2.8 kg on placebo over 56 weeks, and in LEADER it lowered major cardiovascular events in high-risk type 2 diabetes (HR 0.87). A 2025 Cochrane review rated most obesity outcomes low to moderate certainty.
Read full reportWhat is Liraglutide?
Liraglutide is a once-daily injectable GLP-1 receptor agonist, prescribed for type 2 diabetes and, at a higher dose, for chronic weight management in adults and in adolescents 12 and older who weigh more than 60 kg and have obesity. It was the first GLP-1 drug with a positive cardiovascular outcome trial. In the 56-week SCALE trial, 3,731 adults on liraglutide 3.0 mg plus lifestyle counseling lost 8.4 kg on average versus 2.8 kg on placebo (Pi-Sunyer 2015). An independent Cochrane review later confirmed that liraglutide raises the likelihood of meaningful weight loss, while rating several other obesity outcomes low or very low certainty.
From the BioHarmony report, reviewed Oct 13, 2026.
Saved on this device only.
How it is thought to work
GLP-1 receptor agonism: glucose-dependent insulin release, glucagon suppression, slower gastric emptying, lower appetite
Safety watch-outs
- Severe upper abdominal pain radiating to the back, with or without vomiting: stop and seek urgent care for a pancreatitis check.
- Personal or family history of medullary thyroid carcinoma or MEN 2: liraglutide is contraindicated.
- A neck lump, hoarseness or trouble swallowing: get it evaluated.
- Shakiness, sweating or confusion while also using insulin or a sulfonylurea: treat low blood sugar and have doses reviewed.
- Persistent vomiting or diarrhea with signs of dehydration: seek care, since dehydration can injure the kidneys.
Full risk profile in the BioHarmony report.
Dosing as published
Source-reported figures only. This page does not calculate a personal dose.
Working with a vial? The reconstitution calculator covers mixing math, not dosing advice.
More reported protocols
MembersMembers can compare additional reported doses, schedules, and preparation notes.
Educator coverage (1)
Attributed viewpoints, separate from primary research.
- Tirzepatide vs Liraglutide: Complete Comparison Guide Jay Campbell,
Trust & sourcing
- Last revieweddone
- Next reviewupcoming
FDA-approved liraglutide products exist, including Saxenda for chronic weight management and Victoza for type 2 diabetes.
Primary sources
- FDA proposes to exclude semaglutide, tirzepatide, and liraglutide on 503B bulks list U.S. Food and Drug Administration,
- Saxenda (liraglutide) prescribing information DailyMed, U.S. National Library of Medicine,
Related peptides for weight & metabolic
- 6.1TirzepatideTirzepatide is a once-weekly subcutaneous dual GIP plus GLP-1 receptor agonist with unusually large weight-loss and glycemic effects.
- 6.0MOTS-cMOTS-c is a 16-amino-acid mitochondrial-derived peptide discovered in Lee 2015 that activates AMPK through the folate and purine pathway.
- 6.0TesamorelinTesamorelin is a stabilized GHRH analog that reduced visceral adipose tissue in the landmark Falutz 2007 HIV lipodystrophy Phase 3 trial and has newer support for…
- 5.9Semaglutide (GLP-1 Agonist)Semaglutide is a prescription GLP-1 receptor agonist that produced 14.9% mean weight loss in STEP-1 and cut 3-point MACE by 20% in SELECT, but the 5.5-6.0/10 score holds…
The Ultimate Peptides Guide
Spot stronger candidates, weak evidence, and seller red flags before you buy.